Cover Page

Cite item


In the present paper we consider the problem of innovative treatment of systemic autoimmune diseases for example, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The use of biological therapy is suitable for severe rheumatoid arthritis and promotes remission in 2530% of cases. Application biological therapy (as anti-B cell therapy) in cases of systemic lupus erythematosus severe forms can reduce the immuno activity level, and also leads to the regression of secondary vasculitis in lung tissue and renal parenchyma. The analysis of drugs and principles of treatment of rheumatoid arthritis and systemic lupus erythematosus was done. Particular attention is paid to the safety and efficacy of biological agents and synthetic base anti-inflammatory drugs.


About the authors

V. I. Mazurov

I.I. Mechnikov North-Western State Medical University, St. Petersburg, Russian Federation

Author for correspondence.

доктор медицинских наук, академик РАН, заведующий кафедрой терапии и ревматологии
им. Э.Э. Эйхвальда СЗГМУ им. И.И. Мечникова
Адрес: 191015, Санкт-Петербург, ул. Кирочная, д. 41, тел.: +7 (921) 951-71-88

Russian Federation

E. A. Trofimov

I.I. Mechnikov North-Western State Medical University, St. Petersburg, Russian Federation


кандидат медицинских наук, доцент кафедры терапии и ревматологии им.
Э.Э. Эйхвальда СЗГМУ им. И.И. Мечникова
Адрес: 191015, Санкт-Петербург, ул. Кирочная, д. 41,, тел.: +7 (921) 978-86-26

Russian Federation


  1. Mazurov V.I. Modern methods of diagnosis and treatment of rheumatic diseases. Meditsinskaya immunologiya = Medical immunology. 2001;3(2):187–193.
  2. Mazurov V.I., Lila A.M., Zotkin E.G. Klinicheskaya revmatologiya [Clinical Rheumatology]. Moscow, FOLIANT, 2005. 515 p.
  3. Köhler G., Milstein C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:495–497.
  4. Nasonov E.L. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita. Pod red. E.L. Nasonova [Genetically Engineered Biological Agents in the Treatment of Rheumatoid Arthritis. Edited by E.L. Nasonov]. Moscow, IMA-PRESS, 2013. 549 p.
  5. Danese S., Gomollon F. American college of Rheumatology position statement, 2012. J. Crohn's Colitis. 2013;7:586–589.
  6. Mavers M., Ruderman E.M., Perlman H. Intracellular signal pathways: potential for therapies. Curr. Rheum. Rep. 2009;11:378–385.
  7. Rommel C., Camps M., Ji H. PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol. 2007;7:191–201.
  8. Harris E.D., Firestein G.S. In: Kelley’s Textbook of Rheumatology. 8th edn. Philadelphia, Elsevier Saunders, 2008. P. 1087–1118.
  9. Trofimov E.A., Mazurov V.I., Trofimova T.N., Trofimova A.V., Uvarov S.Yu. Magnetic resonance imaging in the evaluation of the effectiveness of brushes treatment of rheumatoid arthritis. Luchevaya diagnostika i terapiya = Radiation diagnostics and therapy. 2010;31:11–20.
  10. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 2002;15:277–304.
  11. Sibbitt W.L. Jr., Brandt J.R., Johnson C.R., Maldonado M.E., Patel S.R., Ford C.C., Bankhurst A.D., Brooks W.M. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J. Rheumatol. 2002;29:1536–1542.
  12. Ainiala H., Loukkola J., Peltola J., Goldman D, Magder LS, Petri M. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology. 2001;57:496–500.
  13. Hanly J.G. Neuropsychiatric lupus. Curr. Rheumatol. Rep. 2001;3:205–212.
  14. Sakic B., Kolb B., Whishaw I. Q., Gorny G., Szechtman H. Immunosuppression prevents neuronal atrophy in lupus-prone mice: evidence for brain damage induced by autoimmune disease? J. Neuroimmunol. 2000;111(1–2):93–101.
  15. Harel L., Sandborg C., Lee T., von Scheven E. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J. Rheumatol. 2006;33:1873–1877.
  16. Kim J.S., Lee K.S., Koh E.M., Kim S.Y., Chung M.P., Han J. Thoracic involvement of systemic lupus erythematosus: clinical, pathologic, and radiologic findings. J. Comput. Assist. Tomogr. 2000;24(1):9–18.
  17. Hanly J.G., Urowitz M.B., Sanchez-Guerrero J., Bae С., Gordon С., Isenberg D.J. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study. Arthritis Rheum. 2007;56:265–273.

Copyright (c) 2015 "Paediatrician" Publishers LLC

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies